Recent Jobs

  • Principal Regulatory Writer

    Regulatory Professionals
    UK, Cheshire
  • Operations Regulatory CMC – Specialist

    Regulatory Professionals
    UK, Cheshire
  • Senior Regulatory Affairs Associate

    Regulatory Professionals
    London East, UK
  • Product Stewardship Specialist

    Regulatory Professionals
    UK, Scotland
Load more listings

Make your job search easier

Create a candidate account to save jobs for later and have the latest roles and career advice emailed to you.

Register for Job Alerts

Want to see how you compare to the rest of the industry?

Enter your details to receive a complimentary copy of our salary guide delivered to your door.

Life Science Salary Guide

Create an Account

Complete your online profile and make it easier to apply for roles on the move.

Register your Details

Regulatory Professionals is one of the fastest growing global integrated regulatory outsourcing providers with a network of 20,000 pharmaceutical professionals globally. Working exclusively within the regulatory functions of Pharmaceutical, Biotechnology, Medical Device, Consumer health / OTC and Diagnostics industries.

Our integrated regulatory affairs recruitment team is there to support partner organisations of all sizes. Ranging for one regulatory consultant, to deliver a specialist project, to outsourcing functional regulatory teams of over 100+, Regulatory Professionals are able to offer global support partnered with expert local knowledge. Our capabilities also offer contract and permanent regulatory staffing services to allow a 360 degree service range for all aspects of regulatory delivery.

Our regulatory recruitment teams approach is tailored to meet the needs of our partners requirements allowing you to shift internal R&D focus to more strategic activities to improve lifecycle performance.

The benefits of Regulatory Professionals integrated teams are measured not just in the savings that could result in multi-mullion dollar cost reductions, but equally in understanding that delays in any part of the regulatory cycle affect the ability to give patients access to transformational products.

Our integrated teams support your product portfolio by giving you flexibility of resource at the peaks and troughs of the product life cycle, while ensuring you maintain control of strategic regulatory departments. This is supported by consistent, measurable and tracked metrics to maximise accountability.

To find out more about each of the regulatory areas we specialise in, take a look at the following regulatory recruitment services:

•    Regulatory Medical Devices
•    Regulatory Clinical
•    Regulatory CMC
•    Regulatory Submissions and Publishing
•    Regulatory Writing
•    Lifecycle Management

Our experienced specialist recruitment consultants are available to speak to you confidentially about our outsourcing regulatory affairs services. To find out more information or to discuss any of our regulatory vacancies, please call our specialist regulatory affairs recruitment team.

+44 (0)118 9522 797

Contact us today to find out how we can progress your career to the next level

Latest News

FDA approves SK Biopharma’s seizure drug

FDA has given Arvelle Therapeutics’ Xcopri the go-ahead for partial-onset seizures in adults. The emerging company, which is part of a subsidiary of SK Biopharmaceuticals, announced that it has also licensed exclusive rights to develop and commercialise the drug in Europe, with intent to file a Marketing Authorisation Application (MAA) in the first half of

Continue Reading

FDA Approves Alnylam’s RNAi treatment for rare diseases

The FDA has given Alnylam a second US approval for one of its RNA interference (RNAi) drugs for acute hepatic porphyria drug Givlaari. Porphyrias are genetic metabolic disorders caused by an enzyme deficiency in the haem pathway that leads to a build-up of toxic porphyrin molecules in the body, causing attacks that lead to tissue

Continue Reading

FDA give Sandoz FDA approval for filgrastim biosimilar

Novartis unit Sandoz has gained approval from the FDA for its filgrastim biosimilar, Ziextenzo. Ziextenzo is a long-acting form of filgrastim approved to reduce the incidence of infection in cancer patients that are receiving chemotherapy. The Infections tend to be manifested by low white blood cell count and fever in patients with non-myeloid malignancies on

Continue Reading